Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | DDX3X | O00571 | 1/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14155070 | 0.84 | KMT2A (0.51) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL5892586 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL28177397 | 0.81 | ALDH1A1 (0.55) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL28009280 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL732435 | 0.79 | SMN1; SMN2 (0.64) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL11445187 | 0.79 | MAPT (0.68) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL584567 | 0.79 | ALDH1A1 (0.52) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL9655921 | 0.79 | KMT2A (0.54) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL14414997 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL11179084 | 0.79 | MEN1 (0.58) | SMN1; SMN2KMT2AMEN1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022234965-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 보로노이 | 2022-11-10 | — | — | WO | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| EP-2327677-A1 | Mono-nitration of aromatic compounds | F. Hoffmann-La Roche AG (CH) | 2011-06-01 | — | — | EP | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| EP-2016034-A2 | MONO-NITRATION OF AROMATIC COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2009-01-21 | — | — | EP | disclosed |
| US-7429589-B2 | Mono-nitration of aromatic compounds via nitrate salts | HOFFMANN-LA ROCHE INC. (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2007125034-A2 | MONO-NITRATION OF AROMATIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| US-20070255057-A1 | Mono-nitration of aromatic compounds via nitrate salts | CEDILOTE MIALL | 2007-11-01 | — | — | US | disclosed |
| US-7105503-B2 | Pyrazole compounds | QLT INC. (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | SMN1; SMN2 4161/4885KMT2A 2931/4885MEN1 3936/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | SMN1; SMN2 4161/4885KMT2A 2931/4885MEN1 3936/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | SMN1; SMN2 2243/4885KMT2A 4148/4885MEN1 1844/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | SMN1; SMN2 3557/4885KMT2A 3543/4885MEN1 3439/4885 |
| US-20070255057-A1 | Mono-nitration of aromatic compounds via nitrate salts | NOS2, NOS3, NOS1 | SMN1; SMN2 3204/4885KMT2A 2556/4885MEN1 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.